Philip Lienau
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Advanced Breast Cancer Therapies, Cancer Mechanisms and Therapy, Microtubule and mitosis dynamics, DNA Repair Mechanisms
Most-Cited Works
- → The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models(2019)203 cited
- → Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer(2017)178 cited
- → The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer(2013)174 cited
- → BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application(2012)155 cited
- → Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values(2009)154 cited
- → Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity(2016)117 cited
- → Characterization of novel MPS1 inhibitors with preclinical anticancer activity(2013)109 cited
- → Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety(2015)91 cited
- → Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9(2016)81 cited
- → Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases(2008)79 cited